To investigate safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity in Japanese and Caucasian healthy adult male subjects when ONO-4685 is administered as a single-dose by intravenous infusion.

To investigate safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity when ONO-4685 is administered by single-dose intravenous continuous infusion in Japanese and Caucasian healthy adult male subjects. In addition, in Japanese healthy adult male subjects, to investigate dosing condition of Keyhole limpet hemocyanin (KLH) and to investigate safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity when ONO-4685 is administered by single-dose intravenous continuous infusion after treating with KLH.

Inclusion Criteria:

• Japanese healthy adult male subjects (PartA, B, and C)
• Caucasian healthy adult male subjects (Part D)
• Age (at the time of informed consent): ≥20 yeas, ≤ 45 yeas
• Body weight (at the time of screening test): ≥50 kg

Exclusion Criteria:

• Subjects who are on a treatment for or with a history of respiratory, cardiovascular, psychiatric, neurologic, gastrointestinal, immunologic, hepatic, renal, hematopoietic or endocrine and/or other disease.
• Subjects with current or with a history of severe allergy to drugs or foods
• Subjects with current or with a history of drug or alcohol abuse